Evidence map›Paper›PMID 41769606›Full record

ArticleCureus2026

18F-Fluorodeoxyglucose (FDG) PET/CT Follow-Up in Radioiodine-Refractory Papillary Thyroid Carcinoma: A Case Report.

David Gutierrez Albenda, Valeria Armani Arce, Ernesto Balmaceda Araya, Akira Osawa Pivovarov, Álvaro Montoya Porras

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David Gutierrez AlbendaCyclotron-PET/CT Laboratory, University of Costa Rica, San José, CRI.
Valeria Armani ArceSchool of Medicine, University of Costa Rica, San José, CRI.
Ernesto Balmaceda ArayaSchool of Medicine, University of Costa Rica, San José, CRI.
Akira Osawa PivovarovSchool of Medicine, University of Costa Rica, San José, CRI.
Álvaro Montoya PorrasSchool of Medicine, University of Costa Rica, San José, CRI.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid carcinoma is the most frequent endocrine malignancy, and papillary thyroid carcinoma (PTC) is its predominant subtype. Standard initial management includes surgical resection followed by radioactive iodine (¹³¹I) ablation. PET with fluorodeoxyglucose (¹⁸F-FDG) combined with CT (FDG-PET/CT) has emerged as a valuable tool during follow-up, particularly in cases of radioiodine-refractory disease. We report the case of a 67-year-old man with PTC refractory to multiple ¹³¹I therapies, whose disease progression was monitored using serial FDG-PET/CT imaging. This case highlights the role of FDG-PET/CT in guiding treatment selection in advanced PTC.

Indexed as

18f-fdg pet/ctfollow upiodine therapythyroid papillary carcinomathyroid radioiodine-refractory cancer

Identifiers

PMID41769606
PMCPMC12949687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.